معرفی
Tatiana Kudling is a Doctoral Researcher at the Doctoral Programme in Clinical Research at the University of Helsinki, focusing on advanced cancer immunotherapy approaches using oncolytic adenoviruses. Her work explores gene-modified viral vectors encoding cytokines like TNFα and IL-2 to enhance immune responses against solid tumors.
- Email: tatiana.kudling@helsinki.fi
Research Interests: Cancer immunotherapy, oncolytic virology, cytokine gene therapy, tumor microenvironment modulation, and immune checkpoint inhibitors. Her studies aim to overcome resistance to immunotherapies through viral vector engineering and combination strategies.
Publication Trends: Over 28 research outputs (2017–2025) centered on oncolytic adenovirus applications in melanoma, ovarian, pancreatic, and renal cancers. Key themes include PD-L1 inhibition, Lymphocyte activation, and biomarker discovery for treatment monitoring.
Collaborations: Co-authored with leading researchers in virotherapy (e.g., A. Hemminki, A. Kanerva) and immuno-oncology (e.g., M. Donia, J.M. Santos). Involved in clinical trials like PROTA (platinum-resistant ovarian cancer) and TUNIMO (solid tumors).
